JAMA Network Open

OCT 21, 2026 · JOURNAL ARTICLE

Denosumab Therapy Duration and Osteonecrosis of the Jaw and Skeletal Events in Bone-Metastatic Prostate Cancer

JAMA Network Open

Importance Denosumab reduces skeletal-related events in bone-metastatic prostate cancer but carries a cumulative risk of medication-related osteonecrosis of the jaw (ONJ). The trea

OCT 20, 2026 · JOURNAL ARTICLE

Skin Toxic Effects and Survival With Enfortumab Vedotin–Pembrolizumab in Advanced Urothelial Carcinoma

JAMA Network Open

Importance Skin toxic effects are a common early adverse event of enfortumab vedotin plus pembrolizumab (EVP) therapy, but its association with clinical outcomes in patients receiv

OCT 20, 2026 · JOURNAL ARTICLE

Androgen Synthesis Inhibitors vs Androgen Receptor Inhibitors and Survival in Metastatic Hormone-Sensitive Prostate Cancer

JAMA Network Open

Importance In metastatic hormone-sensitive prostate cancer (mHSPC), randomized clinical trials directly comparing androgen deprivation therapy intensification using androgen synthe

OCT 20, 2026 · JOURNAL ARTICLE

Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer

JAMA Network Open

Importance Although cisplatin-based neoadjuvant chemotherapy for patients with localized muscle-invasive blader cancer (MIBC) is associated with improved survival, nearly half of t

OCT 15, 2026 · JOURNAL ARTICLE

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

JAMA Network Open

Importance Lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) is a targeted radioligand therapy approved for patients with metastatic androgen

OCT 15, 2026 · JOURNAL ARTICLE

Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors

JAMA Network Open

Importance Laser therapy is increasingly used to treat genitourinary syndrome of menopause (GSM) in breast cancer survivors, but sham-controlled evidence of benefit remains limited

OCT 12, 2026 · JOURNAL ARTICLE

Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations

JAMA Network Open

Importance Breast cancer subtyping based on immunohistochemistry (IHC) guides systemic therapy where gene expression profiling assays are unavailable, yet its validity against mole

SEP 30, 2026 · JOURNAL ARTICLE

Palliative Care for Advanced Cancer in Medicare Advantage and Physician Networks

JAMA Network Open

Importance Palliative care (PC) is guideline recommended to improve symptoms and quality of life concurrent with cancer-directed therapy for patients with advanced cancer, yet util